Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14).

Andreas Josefsson,Åsa Jellvert,Erik Holmberg,Klaus Brasso,Peter Meidahl Petersen,Sirpa Aaltomaa,Marjaana Luukkaa,Paul Verhagen,Ronald de Wit,Göran Ahlgren,Ove Andrén,Enrique Castellanos,Mihalj Seke,Anders Widmark,Jan-Erik Damber

Acta oncologica (Stockholm, Sweden)（2023）

引用 2|浏览11

暂无评分

摘要

Docetaxel improved PFS in patients starting bicalutamide due to PSA relapse after local therapy or localized disease without local therapy. Confirmatory studies of the efficacy of docetaxel in the setting of PSA-only relapse in addition to endocrine therapies may be justified if longer follow-up will show increased metastatic-free survival.

查看译文

关键词

Prostate cancer,bicalutamide,docetaxel,psa relapse,randomized clinical trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要